---
title: "Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293238010.md"
description: "Tempus AI has committed to acquiring cancer diagnostics company Personalis for $1.5 billion, with the announcement made on Monday. However, the stocks of both medical technology firms experienced a decline in value following the news. This acquisition marks a significant move in the industry, emphasizing Tempus AI's strategic expansion efforts."
datetime: "2026-07-20T16:03:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293238010.md)
  - [en](https://longbridge.com/en/news/293238010.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293238010.md)
generator: "portal-rs"
---

# Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive

Tempus AI has committed to acquiring cancer diagnostics company Personalis for $1.5 billion, with the announcement made on Monday. However, the stocks of both medical technology firms experienced a decline in value following the news. This acquisition marks a significant move in the industry, emphasizing Tempus AI's strategic expansion efforts.

### Related Stocks

- [PSNL.US](https://longbridge.com/en/quote/PSNL.US.md)
- [TEM.US](https://longbridge.com/en/quote/TEM.US.md)
- [TEMT.US](https://longbridge.com/en/quote/TEMT.US.md)

## Related News & Research

- [Tempus AI Diagnostics CEO Thomas Edward Schoenherr reports $188,580 Tempus AI common share sale](https://longbridge.com/en/news/297014369.md)
- [HHS said to be eyeing two new FDA deputy commissioners for technology and drugs](https://longbridge.com/en/news/296945299.md)
- [Promising Artificial Intelligence Stocks To Follow Now - August 24th](https://longbridge.com/en/news/296810260.md)
- [Green Alpha Advisors LLC Takes $904,000 Position in Personalis, Inc. $PSNL](https://longbridge.com/en/news/296676831.md)
- [Andrew Polovin Sells 22,148 Shares of Tempus AI (NASDAQ:TEM) Stock](https://longbridge.com/en/news/296610788.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**